Professional Documents
Culture Documents
ABSTRACT
INTRODUCTION
1310
Yadav et al.
1311
However, the lipase concentration in the pancreas is 100fold greater than in the liver, duodenum, and small bowels
(28). In AP, increased permeability in the basal pole of the
acinar cells accounts for the pronounced rise of the enzyme
in the serum. Usually, serum lipase increases within 4 8 h
after onset of symptoms, peaks at 24 h, and returns to
normal after 8 14 days (29). Lipase assay is fast, reliable,
practical, and almost as sensitive as an amylase assay. The
cost of the lipase assay compares favorably with amylase
assays, and the technique can be available 24 h a day, 7 days
a week in most hospitals.
SENSITIVITY. The sensitivity of lipase ranges from 85%
to 100% (3, 21), with some reporting it to be less sensitive
than serum amylase (3) and others believing it to be more
sensitive than amylase (21, 30). The major advantage of
lipase is an increased sensitivity in acute alcoholic pancreatitis and with late clinical presentation, as lipase remains
elevated longer than does amylase. Clavien et al. (6) found
that in patients with AP who had normal amylase, more than
two thirds had elevated lipase levels. Gumaste et al. have
shown in their study on patients with AP and nonpancreatic
abdominal pain (31) that the sensitivity of lipase levels of
greater than three times normal is much higher than amylase
levels (100% sensitivity and 99% specificity, vs 72% sensitivity and 99% specificity for amylase levels). In a recent
study of ERCP-induced AP (32), mean lipase values were
four times higher than amylase levels 2 h after the procedure
in those who developed AP.
SPECIFICITY. Lipase elevation is not specific to AP, although it may be slightly better than amylase. Apple and
associates (30) have shown that lipase activity is four times
greater than amylase activity in the pancreas. Second, pancreatic tissue in chronic pancreatitis demonstrates a substantial decline in both amylase and lipase activity, with amylase
activity showing a greater decrease compared to lipase (91%
vs 26%). In conditions of extrapancreatic injury, lipase is
also elevated. Mumps, types I and IV hyperlipoproteinemias, peptic ulcer, acute cholecystitis, extrahepatic biliary
obstruction, liver diseases, small bowel obstruction, intestinal infarction, perforated bowel, acute renal failure, fracture
of bone, crush injury, fat embolism, and the postcholecystectomy syndrome are some examples (7, 33). In our study
of patients with diabetic ketoacidosis (34) we found nonspecific elevation of lipase to occur more frequently than
amylase elevation. Recently, inflammatory bowel disease
and familial pancreatic hyperenzymemia have been included among causes of lipase elevation (19, 35).
The reference point determined in different laboratories
may differ even for identical methods (27, 36). Further,
different authors have arbitrarily used different cutoff values. Steinberg et al. (3) have shown that the upper limit of
normal itself provided the best cutoff value. Keim and
associates (5) suggest that 2-fold elevated lipase values
should be used as the cutoff, whereas Gumaste et al. (31)
1312
Yadav et al.
1313
of pancreatic ribonuclease and the need for operative treatment of pancreatic necrosis or abscesses. They found that,
among 24 patients with normal ribonuclease levels, only one
required surgical treatment for abscesses. In contrast, 11 of
13 patients with elevated ribonuclease required surgical
intervention. These relationships need further evaluation in
a large group of patients. The assays are cumbersome and
not currently available for clinical use.
Interleukins
The activation of inflammatory cells that release cytokines
plays an important role in the pathogenesis of the disease.
Various studies have demonstrated that IL-6 and IL-8 peak
within the first 24 h after onset of symptoms and are significantly higher in patients with severe AP (6772). A
study of serum markers in ERCP-induced AP showed that
the earliest peak was of serum IL-8, 12 h after the procedure,
followed by IL-6s peak at 24 h and CRPs peak at 72 h.
Chen and associates (52) have observed that, when compared to serum TNF-, IL-1B, IL-8, and CRP, IL-6 is the
best early predictor (day 1 after admission) of severe AP.
Using a cutoff value of 400 pg/ml, the sensitivity, specificity, and accuracy were 89%, 87%, and 88%, respectively,
on day 1. Furthermore, patients with fatal outcomes showed
the most markedly elevated IL-6 concentrations (25 times
the mean values in severe pancreatitis) on days 1 and 2, and
they remained elevated on day 7. The disadvantage is that
the routine determination of IL-6 is not yet widely available.
A rapid dipstick method for estimation of IL-8 is also under
investigation (72).
In contrast, IL-10 reduces the inflammatory response in
experimental pancreatitis. In humans, Pezzelli and associates (68) have also observed higher levels of IL-10 in the
sera of patients with mild disease.
Tumor Necrosis Factor
The prognostic significance of serum TNF in AP has not
been established, as its release is variable and phasic. deBeaux et al. (73) have shown that the concentration of
soluble TNF receptors is able to differentiate mild, severe,
and fatal attacks of AP. Banks et al. (74) observed no
significant difference between mild and severe AP, whereas
Chen and associates (52) found significantly elevated levels
in severe AP on days 13 but not on days 4 and 7. The role
of TNF assay as a prognostic marker remains unclear.
Other Serum Markers
Preliminary studies indicate serum procalcitonin to be a
valuable marker for the prediction of infected pancreatic
necrosis as well as septic multiorgan failure (75, 76). Several other markers have been evaluated recently to assess the
severity of AP. These include plasma soluble intercellular
adhesion molecule 1 (76, 77), serum levels of extracellular
matrix (78), serum levels of the activation peptide of carboxypeptidase B (79), serum amyloid A (80), and serum
trypsinogen-2 and trypsinogen-2--1-antitrypsin complex
(81). The use of these tests is currently restricted to research
1314
Yadav et al.
settings, and further studies defining their clinical importance in assessment of severity of AP are awaited.
Clinical Practice Recommendations for Serum Tests of
Severity
Although a host of newer serum markers hold promise for
the future, they are still experimental, used in research
settings, and not widely available. Serum CRP is the best
available serum marker presently to assess the severity of
AP. A cutoff level of 150 mg/L is now accepted as a
proven predictor of severity.
URINE TESTS
Diagnosis
Although routine use of urinary amylase is not done widely
to evaluate a patient with AP, recently several studies have
reported the use of urinary dipstick tests for screening cases
of AP in the emergency room (96, 97). A dipstick test for
detecting pancreatic amylase in urine by an immunochromatography principle using the monoclonal antibodies specific for pancreatic amylase in initial studies has shown
promising results (97). The test has a high specificity of 97%
and is likely to become useful in the emergency room
setting. Other tests have reported the clinical utility of the
urine trypsinogen-2 dipstick test in AP for screening patients with suspected AP as well as predicting the severity
(98, 99). In a study of 525 consecutive patients presenting to
the emergency room with abdominal pain, the sensitivity
and specificity of diagnosing AP were 96% and 92%, respectively. All nine patients with severe AP were detected
by the dipstick (98).
Severity
Trypsinogen activation peptides (TAPs) are the highly conserved tetra-1-aspartyl-1-lysyl amino terminal peptides re-
1315
Lipase
Sensitivity
Specificity
Prediction of severity
67100%*
8598%
None
82100%
82100%
None
Comments
Cheap, widely
available
Cheap, widely
available
Serum CRP
Test for severity
Test for severity
Yes
(150 mg/L at
48 h)
Cheap, widely
available, best
available lab
test for severity
Urinary TAPs
Experimental
* Poor sensitivity in hyperlipidemic AP, acute or chronic AP due to alcohol, and delayed estimation.
Better than amylase. Lipase is increasingly being recognized as nonspecific.
CLINICAL PRACTICE RECOMMENDATIONS. The assay of TAPs for determining severity of AP is appealing as
a single marker that is able to provide accurate severity
prediction within 24 h after onset of symptoms. These
encouraging results should be considered preliminary, and
further studies are needed to establish its role in the evaluation of AP. Presently, TAP assays are not widely available.
1316
Yadav et al.
and lipase, and fluid amylase has no clear role in the evaluation of patients with AP. Urinary TAPs within 1224 h
and serum CRP at 48 h are now considered by many to be
good markers for predicting severity of AP. A host of new
serological markers have been investigated in the last few
years to predict the severity of AP early. Some of them show
promise but have yet to prove their superiority.
Reprint requests and correspondence: C. S. Pitchumoni, M.D.,
M.A.C.G., M.P.H., Professor of Medicine and Preventive & Community Medicine, New York Medical College, Director, Department of Medicine & Chief of GI, Our Lady of Mercy Medical
Center, 600 East 233rd Street, Bronx, NY 10466.
Received Feb. 6, 2001; accepted Jan. 15, 2002.
REFERENCES
1. Agarwal N, Pitchumoni CS, Sivaprasad AV. Evaluating tests
for acute pancreatitis. Am J Gastroenterol 1990;85:356 66.
2. Salt WB, Schenker S. Amylaseits clinical significance: A
review of the literature. Medicine 1976;55:269 89.
3. Steinberg WM, Goldstein SS, Davis ND, et al. Diagnostic
assays in acute pancreatitis. Ann Intern Med 1985;102:576
80.
4. Jacobs ML, Daggett WM, Civetta JM, et al. Acute pancreatitis. Analysis of factors influencing survival. Ann Surg
1977;185:4351.
5. Keim V, Teich N, Fiedler F, et al. A comparison of lipase and
amylase in the diagnosis of acute pancreatitis in patients with
abdominal pain. Pancreas 1998;16:459.
6. Clavien PA, Robert J, Meyer P, et al. Acute pancreatitis and
normoamylasemia. Not an uncommon combination. Ann
Surg 1989;210:614 20.
7. Spechler SJ, Dalton JW, Robbins AH, et al. Prevalence of
normal serum amylase levels in patients with acute alcoholic
pancreatitis. Dig Dis Sci 1983;28:8659.
8. Ventrucci M, Pezzilli A, Naldoni P, et al. Serum pancreatic
enzyme behavior during the course of acute pancreatitis.
Pancreas 1987;2:506 9.
9. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin
North Am 1990;19:78391.
10. Warshaw AL, Bellini CA, Lesser PB. Inhibition of serum and
urine amylase activity in pancreatitis with hyperlipemia. Ann
Surg 1975;182:72.
11. Mishkin S, Bates J, OHashi J, et al. Possible mechanisms of
normal amylase activity in hyperlipemic pancreatitis. CMAJ
1976;115:1016 9.
12. Webber J, Fromm D. Assessment, diagnosis, and initial treatment. In: Howard J, Yasuo I, Ihse I, Prinz R, eds. Surgical
diseases of the pancreas, 3rd ed. Baltimore: Williams &
Wilkins 1998:20727.
13. Humphries CC, Adams LJ, Eckfeldt JH, et al. Hyperamylasemia in patients with eating disorders. Ann Intern Med
1987;106:50 2.
14. Lott JA. The value of clinical laboratory studies in acute
pancreatitis. Arch Pathol Lab Med 1991;115:3257.
15. Berk JE, Fridhandler L, Webb SF. Does hyperamylasemia in
the drunken alcoholic signify pancreatitis? Am J Gastroenterol 1979;71:557 62.
16. Dutta SK, Douglass W, Smalls UA, et al. Prevalence and
nature of hyperamylasemia in acute alcoholism. Dig Dis Sci
1981;26:136 41.
17. Clavien PA, Burgan S, Moossa AR. Serum enzymes and the
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
1317
62. Nevalainen TJ. The role of phospolipase A in acute pancreatitis. Scand J Gastroenterol 1980;15:64150.
63. Buchler M, Malfertheiner P, Schadlich M, et al. Role of
phospholipase-A2 in human acute pancreatitis. Gastroenterology 1989;97:1521 6.
64. Bird NC, Goodman AJ, Johnson AG. Serum phospholipase
A2 activity in acute pancreatitis: An early guide to severity.
Br J Surg 1989;76:7312.
65. Mayer J, Rau B, Grewe M, et al. Secretory phospholipase A2
in patients with infected pancreatic necrosis in acute pancreatitis. Pancreas 1998;17:2727.
66. Warshaw AL, Lee KH. Serum ribonuclease elevation and
pancreatic necrosis in acute pancreatitis. Surgery 1979;86:
22734.
67. Gross V, Andreesen R, Leser HG, et al. Interleukin-8 and
neutrophil activation in acute pancreatitis. Eur J Clin Invest
1992;22:200 3.
68. Pezzelli R, Belli P, Miniero R, et al. Serum interleukin-6,
interleukin-8 and alpha-2 microglobulin in early assessment
of severity of acute pancreatitis. Comparison with C-reactive
protein. Dig Dis Sci 1995;40:2341 8.
69. Leser HG, Gross H, Scheibenbogen C, et al. Elevation of
interleukin-6 concentration precedes acute phase response
and reflects severity in acute pancreatitis. Gastroenterology
1991;101:7825.
70. Viedma JA, Perez-Mateo M, Dominquez JE, et al. Role of
interleukin-6 in acute pancreatitis: Comparison with C-reactive protein and phospholipase A. Gut 1992;33:1264 7.
71. Heath DI, Cruickshank A, Gudgeon M, et al. Role of interleukin-6 in mediating the acute phase protein response and
potential as an early means of severity assessment in acute
pancreatitis. Gut 1993;34:415.
72. Rau B, Steinbach G, Mayer J, et al. The role of interleukin-8
in the severity assessment of septic complication in necrotizing pancreatitis. Digestion 1997;58(suppl 2):11.
73. deBeaux AC, Goldie AS, Ross JA, et al. Serum concentration
of inflammatory mediators related to organ failure with acute
pancreatitis. Br J Surg 1996;83:349 53.
74. Banks RE, Evans SW, Alexander D, et al. Is fatal pancreatitis
a consequence of excessive leukocyte stimulation? The role
of tumor necrosis factor alpha. Cytokine 1991;3:6 12.
75. Rau B, Steinbach G, Gansauge F, et al. The potential role of
procalcitonin and interleukin-8 in the prediction of infected
necrosis in acute pancreatitis. Gut 1997;41:832 40.
76. Mandi Y, Farkas G, Takacs T, et al. Diagnostic relevance of
procalcitonin, IL-6, and sICAM-1 in the prediction of infected necrosis in acute pancreatitis. Int J Pancreatol 2000;
28:4351.
77. Kaufmann P, Demel U, Tilz GP, et al. Time course of plasma
intercellular adhesion molecule-1 (sICAM-1) is related to
severity of acute pancreatitis. Hepatogastroenterology 1999;
46:256571.
78. Lohr M, Hummel F, Martus P, et al. Serum levels of extracellular matrix in acute pancreatitis. Hepatogastroenterology
1999;46:326370.
79. Appelros S, Petersson U, Johnson C, et al. Activation peptide
of carboxypeptidase C and anionic trypsinogen as early predictors of the severity of acute pancreatitis. Br J Surg 2001;
88:216 21.
80. Rau B, Steinbach G, Baumgart K, et al. Serum amyloid A
versus C-reactive protein in acute pancreatitis: Clinical value
of an alternative acute-phase reactant. Crit Care Med 2000;
28:736 42.
81. Hedstrom J, Kemppainen E, Andersen J, et al. A comparison
of serum trypsinogen and trypsin-2-alpha-1-antitrypsin complex with lipase and amylase in the diagnosis and assessment
1318
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
Yadav et al.